su011248
Genitourinary Cancer
M.D. Anderson Cancer CenterPhase 2Dormant
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 81/ 100
Competitive context
12 Active assets in the Genitourinary Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Spanish Oncology Genito-Urinary Group | Phase 2 | B |
Atezolizumab British Columbia Cancer Agency | Phase 2 | B |
Ipilimumab Dana-Farber Cancer Institute | Phase 2 | B |
Riluzole University of California, Irvine | Phase 2 | CCC |
Inno-206 University of Illinois at Chicago | Phase 1 | CCC |
View all 16 →
Same molecule, other indications
su011248 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →